The proportions of male subjects were also 71–73% in our reports investigating the effects of SGLT2 inhibitors in patients with type 2 diabetes [11,12], which seems similar to the proportion in the present study. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.